Court Fight Over Patent Purchases Raises Antitrust Questions for Drug Monopolies
A lawsuit between a major health insurer and Amgen is spotlighting whether buying a drug patent application can be used to extend a monopoly, prompting the FTC to raise antitrust concerns.
The dispute pits an unnamed large insurer against biotech giant Amgen over the legality of acquiring a pending drug patent to keep competitors out. Legal scholars say the case could redefine how patent transactions are evaluated under antitrust law. The U.S. Federal Trade Commission has intervened, arguing that such maneuvers may harm payers and consumers. The outcome may lead to broader scrutiny of pharmaceutical patent deals, which are often blamed for high drug prices.
Why it matters
The ruling could change how drug companies use patents, affecting drug prices and market competition for consumers.
In this story
